Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Forbion is a global venture capital firm that originated as ABN AMRO Capital Life Sciences in the 1990s. The firm rebranded to Forbion Capital Partners in 2006 and simplified its name to Forbion in 2018. Headquartered in the Netherlands, Forbion also has offices in Germany and the United States. The firm manages over €5 billion (approximately $5.5 billion) across multiple fund strategies, which cover all stages of (bio-)pharmaceutical drug development.
Forbion's investment approach emphasizes advancing biotech innovations in human health while addressing planetary health challenges through its BioEconomy fund strategy. The firm has established itself as a leader in the biotech sector, with a portfolio that includes 58 active investments and notable exits such as Yellow Jersey/Numab and Mariana Oncology.
Forbion invests in innovative biotech companies across various sectors, including human health and planetary health. The firm targets investments in seed, seed-plus, series A, and growth equity stages, with a check size range that accommodates early-stage and growth-stage companies. Key areas of interest include immunology, oncology, rare diseases, cardiovascular/metabolic diseases, central nervous system disorders, ophthalmology, respiratory diseases, nephrology, and infectious diseases.
Additionally, Forbion's BioEconomy strategy focuses on sustainable solutions in food, agriculture, materials, and environmental technologies. The firm seeks to partner with founders who are addressing unmet medical needs and developing sustainable innovations. Forbion's investment thesis emphasizes the importance of advancing drug development across all stages while supporting companies that contribute to planetary health.
Forbion's portfolio includes a diverse range of companies that are making significant strides in their respective fields. Notable companies include:
In addition to these companies, Forbion has a total of 58 active investments, showcasing its commitment to supporting innovative biotech solutions. The firm has achieved notable exits, including Yellow Jersey/Numab, which was acquired by Johnson & Johnson for $1.25 billion, and Mariana Oncology, which was acquired by Novartis for $1 billion.
Forbion Team: The firm employs over 50 investment professionals across its offices in the Netherlands, Germany, and the United States. Each team member brings a wealth of experience in the biotech sector, contributing to the firm's investment strategies and portfolio management.
To pitch Forbion, founders should use the contact email info@forbion.com or visit their website at forbion.com. A comprehensive pitch deck is essential, detailing the business model, market opportunity, and team qualifications. Forbion typically responds within a few weeks, and warm introductions are preferred but not mandatory.
In recent months, Forbion has been active in raising capital, successfully securing €2 billion across its latest two funds, Growth Opportunities III and Ventures VII. Additionally, the firm closed its BioEconomy Fund I at a hard cap of €200 million in November 2025. Forbion continues to manage a diverse portfolio of 58 active investments, focusing on advancing innovations in both human and planetary health.
What are Forbion's investment criteria?
Forbion focuses on innovative biotech companies that address unmet medical needs and sustainable solutions. The firm invests across various stages, including seed, seed-plus, series A, and growth equity.
How can I apply or pitch to Forbion?
Founders can pitch to Forbion by visiting their website at forbion.com or by emailing info@forbion.com. A detailed pitch deck should be included, outlining the business model, market opportunity, and team background.
What makes Forbion different from other venture capital firms?
Forbion's unique focus on both human health and planetary health sets it apart. The firm emphasizes sustainable solutions through its BioEconomy strategy, targeting advancements in food, agriculture, and environmental technologies.
What is Forbion's geographic scope?
Forbion operates globally, with a strong presence in North America and Europe. The firm has offices in the Netherlands, Germany, and the United States, allowing it to engage with a diverse range of startups.
What is Forbion's post-investment involvement like?
Forbion adds value to its portfolio companies through strategic support in company building, seed funding, and expansion efforts. The firm leverages its extensive network and expertise in the biotech sector to assist its portfolio companies.
What is the typical check size for Forbion's investments?
Forbion's check sizes vary depending on the stage of investment, covering seed, seed-plus, series A, and growth equity stages. Specific amounts are tailored to the needs of the portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.